While NRF2 activation has been regarded as a target for chemoprevention and treatment of proinflammatory diseases [4], the studies in the last decade have demonstrated that NRF2 is constitutively activated in cancer due to somatic mutations in the KEAP1/NRF2 pathway, conferring chemoresistance and radioresistance [5]. Here, KEAP1 is linked to cancer.